Form 4: Catalyst Pharmaceuticals Director Molly Harper Executes Stock Option and Sells Shares

Director Molly Harper of Catalyst Pharmaceuticals exercised stock options and sold the resulting shares on November 27, 2024.

Summary

• Molly Harper, a director at Catalyst Pharmaceuticals, exercised options to purchase 17,500 shares of common stock at a price of $5.78 per share on November 27, 2024.
• Following the exercise of these options, Ms. Harper sold 17,500 shares of common stock on the open market at a price of $22 per share on the same day.
• The sale was conducted for personal reasons and to fund the exercise of the stock options, and not due to any disagreement with the company.
• After these transactions, Ms. Harper directly owns 134,020 options to purchase common stock.

Sentiment

Score: 5

Explanation: The document reflects a neutral event of a director exercising options and selling shares. It is a routine transaction and does not indicate any positive or negative sentiment towards the company.

Management Comments

• The sale of shares was for personal reasons and to fund the exercise price of the stock options, and not as a result of any disagreement with the Company.

Industry Context

This is a routine transaction for a company director and is not unusual. It is common for directors to exercise options and sell shares for personal financial management.

Comparison to Industry Standards

• Stock option exercises and sales by directors are a common practice across the pharmaceutical industry.
• The timing and pricing of these transactions are often influenced by personal financial planning and market conditions.
• Similar transactions can be observed in companies like Biogen, Amgen, and Gilead Sciences, where directors periodically exercise options and sell shares.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine sale by a director.
• The sale does not indicate any change in the company's fundamentals or future prospects.

Key Dates

Keywords

stock options, insider trading, share sale, Catalyst Pharmaceuticals, Molly Harper, director